Systemic Psoriasis Therapeutics in Asia Pacific Markets to 2021 – Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth – Acute Market Reports

Systemic Psoriasis Therapeutics in Asia-Pacific Markets to 2021 – Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth

Browse Full Report Visit :-


GBI Research, the leading business intelligence provider, has released its latest research, “”Systemic Psoriasis Therapeutics in Asia-Pacific Markets to 2021 – Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth””, which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by GBI Research’s team of industry experts.


The report analyzes treatment use patterns, market characterization, the pipeline, and key licensing and co-development deals for psoriasis in the APAC markets of China, India, Japan, and Australia.The report includes –

– A brief introduction to psoriasis, including pathophysiology, etiology, diagnosis, and treatment algorithms

– In-depth analysis of currently marketed drugs, including analysis of safety, efficacy, treatment patterns, and strengths/weaknesses, along with a heat map comparing them in terms of safety and efficacy

– A comprehensive review of the pipeline for psoriasis, including individual analysis of a number of late-stage pipeline drugs likely to enter the market during the forecast period; the pipeline is further analyzed on the basis of phase distribution, molecule type, program type, mechanism of action, and molecular target

– Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration, and program failure rate for each molecule type

Reasons to buy

The report will enhance your decision-making capability by allowing you to –

– Understand the psoriasis pipeline and the factors that indicate that it is becoming more innovative

– Analyze detailed profiles for promising pipeline products and gain insights into how they are likely to compete in the market and who their main competitors will be

– Follow the trends in psoriasis clinical trial size and duration in relation to industry averages

– Assess the potential risk of future developmental programs for psoriasis therapeutics by mechanism of action using recorded clinical trial failure rates

Browse All Reports of This Category :-

1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 9

2 Introduction 10
2.1 Symptoms 11
2.1.1 Skin Manifestations 11
2.1.2 Psychological Impact 11
2.2 Etiology, Co-morbidities and Risk Factors 11
2.2.1 Genetics 11
2.2.2 Psoriatic Arthritis 11
2.2.3 Mental Health Disorders 12
2.2.4 Metabolic Syndrome, Smoking, Diet and Alcohol Consumption 12
2.2.5 Infections 12
2.2.6 Köebner Phenomenon 13
2.2.7 Other Immune-Mediated Diseases 13
2.3 Pathophysiology 13
2.4 Diagnosis 14

3 Marketed Products 19
3.1 Overview 19
3.2 Methotrexate-Based Products 19
3.3 Sandimmune/Neoral (cyclosporine/modified cyclosporin) – Novartis 20
3.4 Humira (adalimumab) – AbbVie 21
3.5 Enbrel (etanercept) – Amgen 23
3.6 Remicade (infliximab) – Janssen Biotech 25
3.7 Stelara (ustekinumab) – Janssen Biotech 26
3.8 Comparative Efficacy and Safety 28

To Get Complete Report @

About Us:

Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the worlds most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.

Contact Us :

Name : Chris Paul


Designation : Global Sales Manager

Toll Free(US/CANADA): +1-855-455-8662

Email :

Website :

SOURCE Columnist of Week